|
Market Closed -
Nasdaq
00:00:00 05/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.6665 USD | +2.70% |
|
+3.35% | -57.82% |
| 08-28 | Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026 | CI |
| 08-28 | Outlook Therapeutics Appoints Kevin Lundquist as CFO | MT |
Company Valuation: Outlook Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 162.3 | - | - |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 244.61% | - | - |
| Enterprise Value (EV) | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 162.3 | 162.3 | 162.3 |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 244.61% | 0% | 0% |
| P/E | -6.2x | -3.94x | -0.92x | -1.32x | -0.59x | -1.15x | -2.82x | 7.41x |
| PBR | 71.9x | 29.6x | - | - | - | - | - | - |
| PEG | - | 0.3x | 0x | 0.1x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | 33.3x | 197x | 3.9x | 0.95x |
| EV / Revenue | - | - | - | - | 0x | 197x | 3.9x | 0.95x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -3.13x | -5.71x | 2.03x |
| EV / FCF | - | -0x | -0x | - | - | -4.16x | -14.8x | 1.2x |
| FCF Yield | - | -20.5% | -74.7% | - | - | -24% | -6.78% | 83.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7 | -6.2 | -4.8 | -4.06 | -1.79 | -0.58 | -0.2367 | 0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 1.413 | 0.824 | 41.57 | 170.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.73 | -63.07 | -53.13 | -71.7 | -67.06 | -51.86 | -28.41 | 80.01 |
| Net income 1 | -53.16 | -66.05 | -58.98 | -75.37 | -62.42 | -62.6 | -36.77 | 20.8 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 43.4000 | 24.4000 | 4.4200 | 5.3400 | 1.0600 | 0.6665 | 0.6665 | 0.6665 |
| Nbr of stocks (in thousands) | 8,767 | 11,307 | 13,012 | 23,656 | 44,420 | 243,448 | - | - |
| Announcement Date | 22/12/21 | 29/12/22 | 22/12/23 | 27/12/24 | 19/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.15x | - | - | - | 162M | |
| 33.15x | 5.95x | 17.82x | 0.98% | 48.93B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.41x | 29.72x | -.--% | 40.73B | |
| 28.42x | 8.6x | 21.8x | 0.4% | 33.52B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 24.24x | 2.11x | 9.11x | 1.11% | 14.67B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 28.38x | 35.07x | 13.80x | 0.31% | 28.6B | |
| Weighted average by Cap. | 27.24x | 47.36x | 12.31x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OTLK Stock
- Valuation Outlook Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
